NASDAQ · UTMDHealthcareSurgical Instruments

Utah Medical Products Inc (UTMD)

$70.02−0.75%
Close Nov 3, 2026 · split-adjusted
Nov 2, 2026$70.66▲ 20.80% in range
Nov 3, 2025Low $53.80 · High $76.66Nov 2, 2026
What changed · written from our data
As of Nov 3, 2026

Utah Medical Products closed at $70.02 on Nov 3, down 0.75%, 8.7% below its 52-week closing high. Volume of 29.6K shares was 0.70× its 20-day average (below normal).

Split-adjusted performance: -4.5% over one month, +8.0% over six months, +20.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $8.53M, down 14.3% from a year earlier, with a net margin of 31.5%.

Short interest was 140.2K shares at the Oct 15 settlement, down 7.7% from the prior report (4.7% of float, 3.6 days to cover).

Market cap$222.3M3.2M shares
Revenue · quarter$8.5M−14.3% YoY
Diluted EPS$0.84−10.6% YoY
P/E · TTM21.2×P/S 6.2×
Net margin31.5%Gross 55.8%
Dividend yield1.77%$0.31 last paid
52-week range53.80 – 76.66−8.7% from high
Volume29.6K0.70× 20-day avg
Volatility · 60d25.1%Annualised
Short % of float4.7%3.6 days to cover
Net cash$87.5MCash $87.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −4.2%1M −4.5%3M −1.7%6M +8.0%YTD +25.1%1Y +20.5%3Y −9.1%5Y −29.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum67
Revenue growth9
Net margin98
Value (low P/E)60
Size45

Industry medians: 6-month return −9.7%, revenue growth +8.9%, net margin −8.2%, P/E 28.1×.

Short interest

Details →
Shares short140.2K−7.7% vs prior
Days to cover3.6Settled Oct 15
% of float4.7%
Short vol. 10d69.2%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
UTMDUtah Medical Products$70.02−0.75%+8.0%−14.3%31.5%21.2$222.3M
TLSITriSalus Life Sciences$3.48−4.13%−24.5%+1.7%−80.5%—$214.3MCompare
OSUROraSure Technologies$3.53+2.17%+17.7%−1.9%20.4%—$243.5MCompare
INFUInfuSystem Holdings$12.80−7.51%+20.5%+2.6%8.7%29.8$254.9MCompare
PROFProfound Medical$6.99+3.86%−3.9%+12.3%−384.2%—$255.4MCompare
PDEXPro-Dex Inc New$60.24+4.49%+7.6%+11.0%14.8%16.0$192.8MCompare
NEGGNewegg Commerce$9.19−5.36%−70.9%———$192.8MCompare
ANIKAnika Therapeutics$19.45+0.21%+30.1%+15.6%10.1%—$260.3MCompare
TMCITreace Medical Concepts$4.28+0.23%+127.7%−4.2%−35.0%—$278.3MCompare

Quick answers

What does Utah Medical Products do?
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology.
What is UTMD's market cap?
$222.31M, based on the Nov 3 close of $70.02.
What is UTMD's P/E ratio?
21.2× trailing-twelve-month earnings of $10.49M.
Does Utah Medical Products pay a dividend?
Yes. The latest regular dividend was $0.31 per share (ex-date Sep 17), an annualised yield of 1.77%.
How much of UTMD is sold short?
140.2K shares, 4.7% of float, as of Oct 15, 2026.
What sector is UTMD in?
Healthcare, in the Surgical Instruments industry.

About Utah Medical Products

Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.

HQ: Midvale, UT152 employeesListed Dec 1, 1982utahmed.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology